Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
- Global Families Turn to Young Travelers Concierge Amid Rising Safety Concerns in the U.S
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
* HMBD ~ Hummingbird Bioscience, a data-driven precision biotherapeutics company, announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will summarize the Phase 1 clinical trial design for HMBD-002.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
- Mentor Agile Empowers Illinois Residents with Free Access To Product Management Training
- Midwest Pond Features & Landscapes Hits 100 Cleanouts This Spring, Expands Services Across Chicago
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Beyond Finance Wins Gold Stevie® Award for Customer Service Department of the Year in 23rd Annual American Business Awards
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
Filed Under: Business
0 Comments
Latest on illi News
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Mayor Brandon Johnson Appoints Francisco Velez as Executive Director of the Chicago Office of Emergency Management and Communications
- Chicago City Council Passes Mayor Johnson's Landmark Green Social Housing Ordinance
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- Transfer Pricing Expert Andrew O'Brien-Penney Joins The Brattle Group as Principal
- Naperville Fire Department Invites Community Members to Fire Prevention Presentation on May 22
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- DR Instruments Inc Expands Lab Apparel Line with New 100% Cotton Lab Coats for Adults and Youth
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- Powerhouse Dynamics to Showcase Groundbreaking OilSmart by Open Kitchen® Solution at National Restaurant Association Show
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Naperville Welcomes Top Global Leaders Through Americas Competitiveness Exchange Visit
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway